{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:31:24Z","timestamp":1724459484765},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,23]]},"DOI":"10.7759\/cureus.67554","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T09:41:54Z","timestamp":1724406114000},"source":"Crossref","is-referenced-by-count":0,"title":["Pseudomyxoma Peritonei Arising From a Mucinous Ovarian Borderline Tumor Treated With Paclitaxel, Cisplatin, and Bevacizumab: A Case Report"],"prefix":"10.7759","author":[{"given":"Kentaro","family":"Niwa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Niwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Kyogoku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1159\/000052897","article-title":"Pseudomyxoma peritonei: a review of current literature","volume":"51","author":"Sherer DM","year":"2001","unstructured":"Sherer DM, Abulafia O, Eliakim R. Pseudomyxoma peritonei: a review of current literature. Gynecol Obstet Invest. 2001, 51:73-80. 10.1159\/000052897","journal-title":"Gynecol Obstet Invest"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000535","article-title":"A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the peritoneal surface oncology group international (PSOGI) modified Delphi process","volume":"40","author":"Carr NJ","year":"2016","unstructured":"Carr NJ, Cecil TD, Mohamed F, et al.. A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the peritoneal surface oncology group international (PSOGI) modified Delphi process. Am J Surg Pathol. 2016, 40:14-26. 10.1097\/PAS.0000000000000535","journal-title":"Am J Surg Pathol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1067\/j.cpsurg.2008.04.003","article-title":"Pseudomyxoma peritonei","volume":"45","author":"Smeenk RM","year":"2008","unstructured":"Smeenk RM, Bruin SC, van Velthuysen ML, Verwaal VJ. Pseudomyxoma peritonei. Curr Probl Surg. 2008, 45:527-75. 10.1067\/j.cpsurg.2008.04.003","journal-title":"Curr Probl Surg"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33460","article-title":"The mutational landscape and prognostic indicators of pseudomyxoma peritonei originating from the ovary","volume":"148","author":"Wang B","year":"2021","unstructured":"Wang B, Yao J, Ma R, et al.. The mutational landscape and prognostic indicators of pseudomyxoma peritonei originating from the ovary. Int J Cancer. 2021, 148:2036-47. 10.1002\/ijc.33460","journal-title":"Int J Cancer"},{"key":"ref5","article-title":"Pseudomyxoma peritonei: new concepts in diagnosis, origin, nomenclature, and relationship to mucinous borderline (low malignant potential) tumors of the ovary","volume":"2","author":"Ronnett BM","year":"1997","unstructured":"Ronnett BM, Shmookler BM, Sugarbaker PH, Kurman RJ. Pseudomyxoma peritonei: new concepts in diagnosis, origin, nomenclature, and relationship to mucinous borderline (low malignant potential) tumors of the ovary. Anat Pathol. 1997, 2:197-226.","journal-title":"Anat Pathol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-09560-w","article-title":"From the Ronnett to the PSOGI classification system for pseudomyxoma peritonei: a validation study","volume":"28","author":"Rufi\u00e1n-Andujar B","year":"2021","unstructured":"Rufi\u00e1n-Andujar B, Valenzuela-Molina F, Rufi\u00e1n-Pe\u00f1a S, et al.. From the Ronnett to the PSOGI classification system for pseudomyxoma peritonei: a validation study. Ann Surg Oncol. 2021, 28:2819-27. 10.1245\/s10434-020-09560-w","journal-title":"Ann Surg Oncol"},{"key":"ref7","doi-asserted-by":"crossref","DOI":"10.1097\/IGC.0000000000000327","article-title":"Prognostic significance of Sugarbaker's peritoneal cancer index for the operability of ovarian carcinoma","volume":"25","author":"Lampe B","year":"2015","unstructured":"Lampe B, Kroll N, Piso P, Forner DM, Mallmann P. Prognostic significance of Sugarbaker's peritoneal cancer index for the operability of ovarian carcinoma. Int J Gynecol Cancer. 2015, 25:135-44.","journal-title":"Int J Gynecol Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2011.03207.x","article-title":"Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study","volume":"119","author":"Deraco M","year":"2012","unstructured":"Deraco M, Virz\u00ec S, Iusco DR, et al.. Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study. BJOG. 2012, 119:800-9. 10.1111\/j.1471-0528.2011.03207.x","journal-title":"BJOG"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2018.10.004","article-title":"Clinical validation of newly developed multiplex kit using Luminex xMAP technology for detecting simultaneous RAS and BRAF mutations in colorectal cancer: results of the RASKET-B study","volume":"20","author":"Taniguchi H","year":"2018","unstructured":"Taniguchi H, Okamoto W, Muro K, et al.. Clinical validation of newly developed multiplex kit using Luminex xMAP technology for detecting simultaneous RAS and BRAF mutations in colorectal cancer: results of the RASKET-B study. Neoplasia. 2018, 20:1219-26. 10.1016\/j.neo.2018.10.004","journal-title":"Neoplasia"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-022-02167-z","article-title":"Performance of Idylla(\u2122) RAS-BRAF mutation test for formalin-fixed paraffin-embedded tissues of colorectal cancer","volume":"27","author":"Makutani Y","year":"2022","unstructured":"Makutani Y, Sakai K, Yamada M, et al.. Performance of Idylla(\u2122) RAS-BRAF mutation test for formalin-fixed paraffin-embedded tissues of colorectal cancer. Int J Clin Oncol. 2022, 27:1180-7. 10.1007\/s10147-022-02167-z","journal-title":"Int J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2013-202023","article-title":"Mucinous tumours of appendix and ovary: an overview and evaluation of current practice","volume":"67","author":"Rouzbahman M","year":"2014","unstructured":"Rouzbahman M, Chetty R. Mucinous tumours of appendix and ovary: an overview and evaluation of current practice. J Clin Pathol. 2014, 67:193-7. 10.1136\/jclinpath-2013-202023","journal-title":"J Clin Pathol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.47","article-title":"Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms","volume":"108","author":"Nishikawa G","year":"2013","unstructured":"Nishikawa G, Sekine S, Ogawa R, et al.. Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms. Br J Cancer. 2013, 108:951-8. 10.1038\/bjc.2013.47","journal-title":"Br J Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw314","article-title":"Toward the molecular dissection of peritoneal pseudomyxoma","volume":"27","author":"Pietrantonio F","year":"2016","unstructured":"Pietrantonio F, Perrone F, Mennitto A, et al.. Toward the molecular dissection of peritoneal pseudomyxoma. Ann Oncol. 2016, 27:2097-103. 10.1093\/annonc\/mdw314","journal-title":"Ann Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e10877","article-title":"Rapid recurrence of a ruptured mucinous borderline ovarian tumor harboring K-RAS mutation followed by progression into anaplastic carcinoma with TP53 mutation","volume":"8","author":"Yang Y","year":"2022","unstructured":"Yang Y, Guan Y, Xu M, Liu J. Rapid recurrence of a ruptured mucinous borderline ovarian tumor harboring K-RAS mutation followed by progression into anaplastic carcinoma with TP53 mutation. Heliyon. 2022, 8:e10877. 10.1016\/j.heliyon.2022.e10877","journal-title":"Heliyon"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12113774","article-title":"Treatment of peritoneal surface malignancies by cytoreductive Surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in Spain: results of the national registry of the Spanish group of peritoneal oncologic surgery (REGECOP)","volume":"12","author":"Manzanedo I","year":"2023","unstructured":"Manzanedo I, Pereira F, Cascales-Campos P, et al.. Treatment of peritoneal surface malignancies by cytoreductive Surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in Spain: results of the national registry of the Spanish group of peritoneal oncologic surgery (REGECOP). J Clin Med. 2023, 12:3774-87. 10.3390\/jcm12113774","journal-title":"J Clin Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2020.11.140","article-title":"Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for limited peritoneal metastasis. The PSOGI international collaborative registry","volume":"47","author":"Arjona-Sanchez A","year":"2021","unstructured":"Arjona-Sanchez A, Aziz O, Passot G, et al.. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for limited peritoneal metastasis. The PSOGI international collaborative registry. Eur J Surg Oncol. 2021, 47:1420-6. 10.1016\/j.ejso.2020.11.140","journal-title":"Eur J Surg Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1159\/000270179","article-title":"Bevacizumab for the treatment of non-resettable pseudomyxoma peritonei associated with mucinous ovarian tumor of low malignant potential - a comparison of two cases","volume":"3","author":"Winer I","year":"2009","unstructured":"Winer I, Buckanovich RJ. Bevacizumab for the treatment of non-resettable pseudomyxoma peritonei associated with mucinous ovarian tumor of low malignant potential - a comparison of two cases. Case Rep Oncol. 2009, 3:1-8. 10.1159\/000270179","journal-title":"Case Rep Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/284003-pseudomyxoma-peritonei-arising-from-a-mucinous-ovarian-borderline-tumor-treated-with-paclitaxel-cisplatin-and-bevacizumab-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T09:42:00Z","timestamp":1724406120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/284003-pseudomyxoma-peritonei-arising-from-a-mucinous-ovarian-borderline-tumor-treated-with-paclitaxel-cisplatin-and-bevacizumab-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,23]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.67554","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,23]]}}}